ArticleCell death & disease2016
Hsa-miR-623 suppresses tumor progression in human lung adenocarcinoma.
Article in Cell death & disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells.Respiratory research · 2017Trial
- Circulating circular RNA hsa_circ_0023179 acts as a diagnostic biomarker for non-small-cell lung cancer detection.Journal of cancer research and clinical oncology · 2023Article
- Interactions between miRNAs and Double-Strand Breaks DNA Repair Genes, Pursuing a Fine-Tuning of Repair.International journal of molecular sciences · 2022Review
- Differential miRNA Expression in Human Macrophage-Like Cells Infected withJournal of fungi (Basel, Switzerland) · 2021Article
- Five Circular RNAs in Metabolism Pathways Related to Prostate Cancer.Frontiers in genetics · 2021Article
- CircRNA ZNF609 Knockdown Represses the Development of Non-Small Cell Lung Cancer via miR-623/FOXM1 Axis.Cancer management and research · 2021Article
- MicroRNA-623 inhibits tumor progression and is a predictor of poor prognosis of breast cancer.Oncology letters · 2020Article
- miR-21-5p promotes lung adenocarcinoma cell proliferation, migration and invasion via targeting WWC2.Cancer biomarkers : section A of Disease markers · 2020Observational
- Bioinformatics and functional analyses of key genes in smoking-associated lung adenocarcinoma.Oncology letters · 2019Article
- MicroRNA-623 Targets Cyclin D1 to Inhibit Cell Proliferation and Enhance the Chemosensitivity of Cells to 5-Fluorouracil in Gastric Cancer.Oncology research · 2018Article
- Regulation of DNA Double-Strand Break Repair by Non-Coding RNAs.Molecules (Basel, Switzerland) · 2018Review
- Microarray expression profile and analysis of circular RNA regulatory network in malignant pleural effusion.Cell cycle (Georgetown, Tex.) · 2018Article
- Cloning of canine Ku80 and its localization and accumulation at DNA damage sites.FEBS open bio · 2017Article
- Novel circular RNA expression profiles reflect progression of patients with hypopharyngeal squamous cell carcinoma.Oncotarget · 2017Article
Corrections and comments
- Correction · 2018-08-06Error in Image ·
- Correction · 2017-05-25Error in Image ·
- Retraction · 2019-01-25Contamination of Cell Lines/Tissues · Unreliable Results and/or Conclusions ·
- Erratum issued
- Erratum issued
- Retracted
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our previous study revealed that Ku80 was overexpressed in lung cancer tissues and hsa-miR-623 regulated the Ku80 expression; however, the detailed function of hsa-miR-623 in lung cancer was unclear. We identified that hsa-miR-623 bound to the 3'-UTR of Ku80 mRNA, thus significantly decreasing Ku80 expression in lung adenocarcinoma cells. Hsa-miR-623 was downregulated in lung adenocarcinoma tissues compared with corresponding non-tumorous tissues, and its expression was inversely correlated with Ku80 upregulation. Downregulation of hsa-miR-623 was associated with poor clinical outcomes of lung adenocarcinoma patients. Hsa-miR-623 suppressed lung adenocarcinoma cell proliferation, clonogenicity, migration and invasion in vitro. Hsa-miR-623 inhibited xenografts growth and metastasis of lung adenocarcinoma in vivo. Ku80 knockdown in lung adenocarcinoma cells suppressed tumor properties in vitro and in vivo similar to hsa-miR-623 overexpression. Further, hsa-miR-623 overexpression decreased matrix metalloproteinase-2 (MMP-2) and MMP-9 expression levels, with decreased ERK/JNK phosphorylation. Inhibition of hsa-miR-623 or overexpression of Ku80 promoted lung adenocarcinoma cell invasion, activated ERK/JNK phosphorylation and increased MMP-2/9 expressions, which could be reversed by ERK kinase inhibitor or JNK kinase inhibitor. In summary, our results showed that hsa-miR-623 was downregulated in lung adenocarcinoma and suppressed the invasion and metastasis targeting Ku80 through ERK/JNK inactivation mediated downregulation of MMP-2/9. These findings reveal that hsa-miR-623 may serve as an important therapeutic target in lung cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.